Paul Tudor Jones Nuvalent, Inc. Transaction History
Tudor Investment Corp Et Al
- $19.2 Billion
- Q2 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Nuvalent, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 12,788 shares of NUVL stock, worth $1.32 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
12,788
Previous 33,042
61.3%
Holding current value
$1.32 Million
Previous $2.48 Million
60.9%
% of portfolio
0.01%
Previous 0.02%
Shares
6 transactions
Others Institutions Holding NUVL
# of Institutions
178Shares Held
56.6MCall Options Held
527KPut Options Held
131K-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$2.06 Billion31.83% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.57MShares$472 Million14.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.78MShares$390 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$312 Million0.01% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA2.7MShares$278 Million41.86% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $4.44B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...